Search - tctmd.com

Displaying 21 - 35 of 35

Sort: Relevancy | Date

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

News Daily News

AHA Seeks to Drive Down Amputations 20% by 2030

L.A. McKeown

April 01, 2021

News Daily News

No Paclitaxel Death Signal in VA Data Out to 3 Years

L.A. McKeown

February 11, 2021

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Daily News

Black Patients More Likely to Undergo Amputation for Critical Limb Ischemia

March 28, 2013

Advertisement

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

AHA Seeks to Drive Down Amputations 20% by 2030

No Paclitaxel Death Signal in VA Data Out to 3 Years

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Black Patients More Likely to Undergo Amputation for Critical Limb Ischemia

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content